Evidence map›Paper›PMID 39340704›Full record

SynthesisInternational journal of clinical oncology2024

Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with highly emetogenic risk antineoplastic agents: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology.

Ayako Yokomizo, Kazuhisa Nakashima, Arisa Iba, Kenji Okita, Makoto Wada, Keiko Iino, Tatsuo Akechi, Hirotoshi Iihara, Chiyo K Imamura, Ayako Okuyama and 18 more

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in International journal of clinical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Ayako YokomizoDepartment of Early Clinical Development, Kyoto University Graduate School of Medicine, 54 Kawaharacho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.ORCID http://orcid.org/0000-0002-8255-794X
Kazuhisa NakashimaFaculty of Medicine, Department of Internal Medicine, Division of Medical Oncology & Respiratory Medicine, Shimane University, 89-1 Enya-Cho, Izumo, Shimane, 693-8501, Japan. kazuhin@med.shimane-u.ac.jp.
Arisa IbaInstitute for Global Health Policy Research, Bureau of International Health Cooperation, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku, Tokyo, 162-8655, Japan.
Kenji OkitaDepartment of Surgery, Otaru Ekisaikai Hospital, 1-4-1, Inaho, Otaru, Hokkaido, 047-0032, Japan.
Makoto WadaDepartment of Psycho-Oncology and Palliative Medicine, Osaka International Cancer Institute, Otemae 3-1-69, Chuo-ku, Osaka, 541-8567, Japan.
Keiko IinoSchool of Nursing, National College of Nursing School of Nursing, National College of Nursing, Japan, 1-2-1, Umezono, Kiyose, Tokyo, 204-8575, Japan.
Tatsuo AkechiDepartment of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan.
Hirotoshi IiharaDepartment of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu, Gifu, 501-1194, Japan.
Chiyo K ImamuraAdvanced Cancer Translational Research Institute, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan.
Ayako OkuyamaGraduate School of Nursing Science, St. Luke's International University, 10-1 Akashi-cho, Chuo-ku, Tokyo, 104-0044, Japan.
Keiko OzawaDivision of Survivorship, Institute for Cancer Control, National Cancer Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Yong-Il KimDivision of Medical Oncology, Yodogawa Christian Hospital, 1-7-50 Kunijima, Higasiyodogawa-ku, Osaka, 533-0024, Japan.
Hidenori SasakiDivision of Medical Oncology, Hematology and Infectious Disease, Fukuoka University Hospital, 7-45-1, Nanakuma, Jonan-ku, Fukuoka, Fukuoka, 814-0180, Japan.
Eriko SatomiDepartment of Palliative Medicine, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Masayuki TakedaDepartment of Cancer Genomics and Medical Oncology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8521, Japan.
Ryuhei TanakaDepartment of Pediatric Hematology/Oncology, International Medical Center, Saitama Medical University, 1398-1 Yamane, Hidaka, Saitama, 350-1298, Japan.
Takako Eguchi NakajimaDepartment of Early Clinical Development, Kyoto University Graduate School of Medicine, 54 Kawaharacho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
Naoki NakamuraDepartment of Radiation Oncology, St. Marianna University, 2-16-1, Sugao, Miyamae, Kawasaki, Kanagawa, 216-8511, Japan.
Junichi NishimuraDepartment of Gastroenterological Surgery, Oisana International Cancer Institute, 3-1-69, Otemae, Chuoku, Osaka, 541-8567, Japan.
Mayumi NodaNon-Profit Organization Sasaeau-Kai "Alpha", 518-7 Kawado-cho, Chuo-ku, Chiba-shi, Chiba, 260-0802, Japan.
Kazumi HayashiDepartment of Clinical Oncology and Hematology, The Jikei University School of Medicine, 3-25-8 Nishi-Shinbashi Minato-ku, Tokyo, 105-8461, Japan.
Takahiro HigashiDepartment of Public Health and Health Policy, The University of Tokyo, 7-3-1 Hongo, Bunkyoku, Tokyo, 113-0033, Japan.
Narikazu BokuDepartment of Oncology and General Medicine, IMSUT Hospital, Institute of Medical Science, University of Tokyo, 4-6-1, Shiroganedai, Minatoku, Tokyo, 108-8639, Japan.
Koji MatsumotoDivision of Medical Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi, Hyogo, 673-0021, Japan.
Yoko MatsumotoNon-Profit Organization Ehime Cancer Support "Orange-no-kai", 3-8-24 FurukawaMinami, Matsuyama, Ehime, 790-0943, Japan.
Nobuyuki YamamotoInternal Medicine III, Wakayama Medical University, Kimiidera 811-1, Wakayama, Wakayama, 541-8509, Japan.
Kenjiro AogiDepartment of Breast Surgery, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minamiumemoto-matchi, Matsuyama, Ehime, 791-0280, Japan.
Masakazu AbeDepartment of Obstetrics and Gynecology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Chuo-ku, Hamamatsu, Shizuoka, 431-3192, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChemotherapy-induced nausea and vomiting (CINV) are common side effects, classified according to timing and severity. Conventional agents such as dexamethasone are effective but have various side effects. For moderately emetogenic chemotherapy, dexamethasone-sparing antiemetic therapies have been developed to minimize these side effects. This systematic review evaluated the efficacy and safety of dexamethasone-sparing antiemetic therapy for highly emetogenic chemotherapy (HEC).

methodsWe performed a thorough literature search for studies related to dexamethasone-sparing antiemetic therapy with neurokinin-1 antagonists (NK

resultsTwo reviewers independently assessed the 425 records and 12 full-text articles were evaluated for eligibility. Two studies were included in the qualitative and meta-analyses. These studies included anthracycline-cyclophosphamide (AC) regimens and cisplatin-based regimens, with palonosetron as the serotonin receptor antagonist. In the two studies, no difference was found in the prevention of vomiting (delayed complete response). However, non-inferiority was not demonstrated in the subgroup that received cisplatin-containing regimens. Delayed complete control showed different results for nausea prevention; however, there was no significant difference in the meta-analysis. Only one report has shown non-inferiority for delayed total control. Although the strength of evidence for individual outcomes varied, there was no difference in the duration of dexamethasone administration.

conclusionsThis systematic review and meta-analysis revealed that dexamethasone-sparing antiemetic therapy with NK

Indexed as

AntiemeticsAntineoplastic Combined Chemotherapy ProtocolsDexamethasoneNauseaVomitingAntineoplastic AgentsCisplatinHumansJapanNeoplasmsNeurokinin-1 Receptor AntagonistsPalonosetronPractice Guidelines as TopicAntiemeticsAntineoplastic AgentsCisplatinDexamethasoneNeurokinin-1 Receptor AntagonistsPalonosetronChemotherapy-induced nausea and vomitingDexamethasoneHighly emetogenic chemotherapyMeta-analysisSparing

Identifiers

PMID39340704

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.